Engineered Transaminases for High-Purity Chiral Tryptamine Synthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for preparing chiral α-substituted tryptamine and tryptamine analogs are time-consuming, require harsh reaction conditions, and have limited efficiency and cost-effectiveness, especially in achieving high enantiomeric excess of the desired chiral compound.
Innovation Solution
Engineered transaminase polypeptides with specific residue differences, such as X14V, X163L, and X86D, are developed to efficiently convert prochiral ketone substrates into chiral tryptamine derivatives under mild conditions, offering improved activity, stability, and stereoselectivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If separation/isolation of desired isomer or chemical asymmetric synthesis is used to prepare chiral α-carbon substituted tryptamine, then enantiomeric excess is improved, but time consumption and process complexity increase
Solution Approach 1:
The patent applies parameter changes by modifying amino acid residues at specific positions (X14, X86, X163) in the transaminase enzyme sequence to optimize catalytic activity and stereoselectivity. This engineered enzyme achieves high enantiomeric excess while operating under milder, faster conditions compared to traditional separation or chemical synthesis methods.
Solution Approach 2:
The patent replaces mechanical separation processes with a biocatalytic approach using engineered transaminase enzymes. This substitution eliminates the need for time-consuming physical separation of isomers while achieving high enantiomeric excess through enzyme-catalyzed asymmetric synthesis.
2Manufacturing precision
If chemical asymmetric synthesis with chiral starting compounds is used, then enantiomeric excess is improved, but reaction conditions become harsher and synthesis routes more complex
Solution Approach 1:
The patent modifies enzyme parameters through site-directed mutagenesis at specific residue positions to create a biocatalyst that operates under mild physiological conditions. This eliminates the need for harsh chemical reagents and complex multi-step synthesis routes while maintaining high stereoselectivity.
Solution Approach 2:
The engineered transaminase enzyme performs self-service by inherently providing both the catalytic function and the chiral environment needed for asymmetric synthesis. The enzyme's active site architecture automatically ensures high enantiomeric excess without requiring external chiral auxiliaries or complex reaction setups.
3Ease of manufacture
If traditional transaminase enzymes are used for conversion, then cost-effectiveness is improved, but activity and stability are insufficient
Solution Approach 1:
The patent employs parameter changes through rational design of amino acid substitutions at key positions (X14V, X86D, X163L) to enhance enzyme activity and stability. These targeted modifications improve catalytic efficiency and operational stability, making the process more productive while maintaining cost-effectiveness through a relatively simple engineering approach.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered transaminases achieve high enantiomeric excess (>90%) and increased activity, stability, and reduced inhibition, facilitating cost-effective production of chiral tryptamine derivatives.
Implementation Method 1
Engineered transaminase polypeptides with specific residue differences, such as X14V, X163L, and X86D, are developed to efficiently convert prochiral ketone substrates into chiral tryptamine derivatives under mild conditions
Data Source
AI summary
The present disclosure provides engineered transaminase polypeptides for the production of amines, polynucleotides encoding the engineered transaminases, host cells capable of expressing the engineered transaminases, and methods of using the engineered transaminases to prepare compounds useful in the production of active pharmaceutical agents.